TABLE 1.

HIF-1α related clinical studies in BC.

Drug	Status	Phase	Main Outcomes	Toxicity	NCT Number
Digoxin	Completed	Phase 2	There was not enough data to analyze HIF-1alpha expression because of the limited tumor samples	No over grade 2 adverse event related to digoxin occurred	NCT01763931
Vinorelbine	Completed	Phase 2	The study was terminated early	Elevated liver enzymes (grade 3) 22.2%, Febrile infection (grade 5) 11.1%	NCT03007992
Paclitaxel plus bevacizumab	Completed		There was no significant difference between HIF-1alpha polymorphism and longer PFS in patients treated with paclitaxel and bevacizumab		NCT01935102
Bevacizumab, docetaxel	Completed	Phase 2		The rate of serious adverse events is about 18.06% and the rate of other adverse events is 98.61% in total	NCT00559754
Propofol, Sevoflurane	Unknown	Not Applicable			NCT03005860